Suchergebnisse - "2019 novel coronavirus"

PubPharm (885)

71

Scientometric assessment of scientific documents published in 2020 on herbal medicines used for COVID-19

enthalten in: Journal of herbal medicine | 2022

von Atlasi, R. | Ramezani, A. | Tabatabaei-Malazy, O. | +3

72

Efficacy of polyherbal formulations for prevention of COVID-19 infection in high-risk subjects : A randomized open-label controlled clinical trial

enthalten in: Phytotherapy research : PTR | 2022

von Chandra, K. | Das, A. | Banday, S. | +9

73

Age-Dependent Effects of COVID-19 Vaccine and of Healthcare Burden on COVID-19 Deaths, Tokyo, Japan

enthalten in: Emerging infectious diseases | 2022

von Ko, Y. | Murayama, H. | Yamasaki, L. | +3

74

Factors Associated with Delayed or Missed Second-Dose mRNA COVID-19 Vaccination among Persons >12 Years of Age, United States

enthalten in: Emerging infectious diseases | 2022

von Meng, L. | Murthy, N. | Murthy, B. | +11

75

CT Imaging Features and Clinical Characteristics of 2019 Novel Coronavirus Pneumonia (COVID-19) During Rehabilitation

enthalten in: Iranian journal of science and technology / A | 2022

von Wang, Y. | Shao, H. | Li, Z. | +4

76

CT Imaging Features and Clinical Characteristics of 2019 Novel Coronavirus Pneumonia (COVID-19) During Rehabilitation

enthalten in: Iranian journal of science and technology | 2022

von Wang, Y. | Shao, H. | Li, Z. | +4

77

Severe hypoxemia in a patient with right ventricular myocardial infarction and SARS-CoV-2 infection

enthalten in: BMC cardiovascular disorders | 2022

von Albuquerque, F. | Lopes, P. | Brízido, C. | +4

78

Severe hypoxemia in a patient with right ventricular myocardial infarction and SARS-CoV-2 infection

enthalten in: BMC cardiovascular disorders | 2022

von Albuquerque, F. | Lopes, P. | Brízido, C. | +4

79

Severe hypoxemia in a patient with right ventricular myocardial infarction and SARS-CoV-2 infection

enthalten in: BMC cardiovascular disorders | 2022

von Albuquerque, F. | Lopes, P. | Brízido, C. | +4

80

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2) : A Virtual Phase 2 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Post-exposure Prophylaxis (PEP) for Newly-infected COVID-19 Patients

enthalten in: ClinicalTrials.gov | 2022